Rational PROTAC design enabled by integrated in silico molecular modeling and in vitro biomimetic affinity assessment
Project Number5R21GM151651-02
Contact PI/Project LeaderCHENG, QUAN JASON
Awardee OrganizationUNIVERSITY OF CALIFORNIA RIVERSIDE
Description
Abstract Text
Rational PROTAC design enabled by integrated in silico molecular modeling and in vitro
biomimetic affinity assessment
Proteolysis targeting chimeras, or PROTACs, have received considerable attention in recent years as
a new class of drugs as compared to traditional inhibitors. These small molecules target selective degradation
of proteins of interest utilizing cell’s native protein degradation machinery including proteosomes and
lysosomes. The benefits of PROTACs stem from an entirely different paradigm of protein targeting, which
provides a unique path to target previously “undruggable” proteins and allows for smaller doses and thus
lower side-effects. However, the complex mechanism of action has left a large knowledge gap towards the
understanding of molecular interactions in different stages, especially on factors that control and stabilize the
ternary complex that leads to ubiquitination and removal. In addition, existing technology lacks of strategies
to model and confirm the linker region of the PROTAC for their roles in affecting the affinities of the warheads
and contributing to the stability of the complex. There has been no report that includes the dynamic membrane
in molecular recognition modeling. A new technical platform that can identify key parameters that impact
formation of stable ternary complex and has the capability of screening molecular interactions with detailed
information on structural insights is highly desired.
To fill the unmet need, we propose to develop a collaborative work plan via a combination of in silico
modeling and in vitro surface plasmon resonance (SPR)-based affinity assessment. We aim to identify
features that lead to formation of stable ternary complexes for efficient PROTAC design. To establish and
prove the technical feasibility, we will study anaplastic lymphoma kinase (ALK), a transmembrane receptor
tyrosine kinase that is an important drug target for a variety of cancers, and an E3 ligase CRBN which has
been used to promote protein degradation. Specifically, we propose three aims: Aim 1. Establish a molecular
modeling platform for rational PROTAC design. The platform incorporates protein dynamics and inputs from
experiments and can adapt various experimental settings such as membrane environment used in SPR. Aim
2. Build and characterize modeled PROTACs and biomimetic membranes. This includes generating
PROTAC-compatible membrane mimics and structural characterization of the interfaces for membrane-bound
proteins for SPR analysis. Aim 3. Investigate interaction properties of PROTAC candidates’ in biomimetic
membranes. This includes on-line in vitro experiments and screening for the PROTACs at stabilizing the
ternary complexes. The identification of stable PROTAC complexes will be used into further exploration into
the understanding of the structure-function relationship of the system.
Public Health Relevance Statement
PROJECT NARRATIVE
The overall objective of this proposal is to develop a workplan for investigating biophysical
dynamics of PROTAC interactions by the combination of in silico modeling and in vitro assay
screening. The research aims to identify structural features that lead to stable ternary complex
formation of drug candidates. The results will provide molecular basis and a technical platform for
effective search of therapeutics with a PROTAC strategy.
No Sub Projects information available for 5R21GM151651-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R21GM151651-02
Patents
No Patents information available for 5R21GM151651-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R21GM151651-02
Clinical Studies
No Clinical Studies information available for 5R21GM151651-02
News and More
Related News Releases
No news release information available for 5R21GM151651-02
History
No Historical information available for 5R21GM151651-02
Similar Projects
No Similar Projects information available for 5R21GM151651-02